Home » Stocks » CTLT

Catalent, Inc. (CTLT)

Stock Price: $99.91 USD -1.57 (-1.55%)
Updated May 13, 2021 2:45 PM EDT - Market open
Market Cap 17.44B
Revenue (ttm) 3.76B
Net Income (ttm) 496.80M
Shares Out 170.34M
EPS (ttm) 2.95
PE Ratio 33.83
Forward PE 32.68
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $99.91
Previous Close $101.48
Change ($) -1.57
Change (%) -1.55%
Day's Open 101.85
Day's Range 99.42 - 102.20
Day's Volume 645,076
52-Week Range 67.97 - 127.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 days ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

6 days ago - Business Wire

Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub. Catalent has acquired Prome...

6 days ago - Benzinga

Catalent (CTLT) delivered earnings and revenue surprises of 7.90% and 5.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Catalent (NYSE:CTLT) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 64.00% over the past year to $0.82, which beat the es...

1 week ago - Benzinga

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

1 week ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell ...

3 weeks ago - Business Wire

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

Other stocks mentioned: MRNA
1 month ago - Zacks Investment Research

CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the ...

Other stocks mentioned: MRNA
1 month ago - Business Wire

Catalent to double output of Moderna vaccine: Report

YouTube video

The U.S. coronavirus vaccine supply could be getting a new boost. According to the Wall Street Journal, contract manufacturer Catalent plans to nearly double its output of the Moderna vaccine, with the ...

Other stocks mentioned: MRNA
1 month ago - CNBC Television

Catalent Inc (NYSE: CTLT) is reportedly expanding its U.S. production of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Mod...

Other stocks mentioned: MRNA
1 month ago - Benzinga

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

1 month ago - Zacks Investment Research

Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT) secured a key U.S. regulator clearance, Bloomberg New...

Other stocks mentioned: JNJ
1 month ago - Benzinga

TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

1 month ago - Business Wire

Despite occasional pullbacks in share price, these growth stocks are expected to continue to create shareholder value during the year. The post 7 Growth Stocks With Compelling Stories appeared first on ...

Other stocks mentioned: CHWY, CRM, HACK, LOUP, ORCL, POOL
1 month ago - InvestorPlace

Catalent is scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant, addressing some concerns over the drugmaker's ability to meet vaccine supply targets in the E...

Other stocks mentioned: JNJ
1 month ago - Reuters

Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles/c...

Other stocks mentioned: JNJ
1 month ago - Reuters

Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon

1 month ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

USNA vs. CTLT: Which Stock Is the Better Value Option?

Other stocks mentioned: USNA
3 months ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, c...

3 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, c...

3 months ago - Business Wire

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 months ago - Zacks Investment Research

Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2021 Results - Earnings Call Transcript

3 months ago - Seeking Alpha

Catalent (CTLT) delivered earnings and revenue surprises of 12.50% and 1.66%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Catalent (NYSE:CTLT) moved higher by 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 40.00% year over year to $0.63, which beat t...

3 months ago - Benzinga

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

3 months ago - Business Wire

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell ...

3 months ago - Business Wire

Catalent is forming a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Feb. 3. The post Earnings Season Preview: Catalent Near Buy Zone With EPS Due a...

3 months ago - Investors Business Daily

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 months ago - Zacks Investment Research

Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.

Other stocks mentioned: CRL, FCX, NOC
4 months ago - 24/7 Wall Street

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

4 months ago - Business Wire

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

4 months ago - Zacks Investment Research

As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.

Other stocks mentioned: AVTR, HCA, HOLX, GH
4 months ago - 24/7 Wall Street

Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

On Friday, Catalent got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Catalent Joins Rank Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Daily.

5 months ago - Investors Business Daily

Catalent Inc (NYSE: CTLT) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets. The Catalent Analyst: Paul Knight upgrade...

5 months ago - Benzinga

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

5 months ago - Zacks Investment Research

Final Trades: Deere, Host Hotels, Retail & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: DE, HST, EA, XRT
6 months ago - CNBC Television

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

6 months ago - Business Wire

Each week, Benzinga will examine a stock that might be considered a little under the radar. You may have never heard of the company before, but chances are you're pretty familiar with the line of work i...

6 months ago - Benzinga

Catalent, Inc. (CTLT) CEO John Chiminski on Q1 2021 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Catalent (CTLT) delivered earnings and revenue surprises of 13.16% and 4.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

6 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

6 months ago - Business Wire

In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks Rank.

Other stocks mentioned: ETSY, FBHS, GNRC, POOL, W
8 months ago - Zacks Investment Research

Etsy (ETSY), Catalent (CTLT), and Teradyne (TER) will join the index on Sept. 21.

Other stocks mentioned: ETSY, TER
8 months ago - Investopedia

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

8 months ago - Zacks Investment Research

About CTLT

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplem... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jul 31, 2014
Stock Exchange
NYSE
Ticker Symbol
CTLT
Full Company Profile

Financial Performance

In 2020, Catalent's revenue was $3.09 billion, an increase of 22.89% compared to the previous year's $2.52 billion. Earnings were $220.70 million, an increase of 60.63%.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Catalent stock is "Strong Buy." The 12-month stock price forecast is 134.70, which is an increase of 34.82% from the latest price.

Price Target
$134.70
(34.82% upside)
Analyst Consensus: Strong Buy